Overview

A Study of AND017 to Treat Anemia in Chronic Kidney Disease Patients on Dialysis

Status:
Not yet recruiting
Trial end date:
2023-08-01
Target enrollment:
Participant gender:
Summary
This is a phase II study to evaluate the safety and efficacy of AND017 in renal anemia patients on dialysis
Phase:
Phase 2
Details
Lead Sponsor:
Kind Pharmaceuticals LLC
Treatments:
Epoetin Alfa